Definition and epidemiology
Emphysema is defined pathologically as permanent, abnormal enlargement of airspaces distal to the terminal bronchioles, caused by destruction of alveolar walls, without obvious fibrosis. It is one of the two major phenotypes of chronic obstructive pulmonary disease (COPD), the other being chronic bronchitis, and most patients show overlapping features of both.
- COPD affects roughly 5-10% of adults over age 40 worldwide, with emphysema-predominant disease most common in long-term smokers.
- Peak incidence is in the 6th-7th decade of life.
- Men have historically had higher rates, but the gap has narrowed as smoking patterns in women have changed.
- A distinct, younger-onset form (often before age 45) occurs in alpha-1 antitrypsin (AAT) deficiency, a genetic cause responsible for a small minority of cases overall but important on exams.
- COPD is a leading cause of death and disability globally, strongly linked to tobacco use and, in lower-income regions, biomass fuel exposure.
- Protease-antiprotease (elastase-antielastase) imbalance underlies alveolar wall destruction.
- Centriacinar emphysema = upper lobes, linked to smoking; panacinar = lower lobes, linked to AAT deficiency.
- Diagnosis requires spirometry showing FEV1/FVC <0.70 that does not fully reverse with bronchodilator.
- DLCO is reduced due to loss of alveolar-capillary surface area, unlike chronic bronchitis.
- 'Pink puffer' describes emphysema phenotype: dyspneic, thin, pursed-lip breathing, near-normal blood gases until late.
- Check serum alpha-1 antitrypsin in early-onset or lower-lobe-predominant emphysema.
- Smoking cessation is the only intervention proven to slow decline in lung function.
- Clubbing is not a feature of emphysema; consider lung cancer or bronchiectasis if present.
Etiology and risk factors
- Cigarette smoking is by far the dominant risk factor, present in the large majority of cases.
- Alpha-1 antitrypsin deficiency causes early-onset, panacinar emphysema, especially affecting the lower lobes; consider this in a nonsmoker or young patient with emphysema.
- Occupational and environmental exposures: coal dust, silica, cadmium, and biomass smoke (cooking fuel) exposure.
- Air pollution and secondhand smoke exposure.
- Age and cumulative pack-years strongly correlate with severity.
- Genetic susceptibility beyond AAT deficiency likely contributes, since not all heavy smokers develop clinically significant emphysema.
Pathophysiology
The central mechanism is a protease-antiprotease imbalance in the lung. Cigarette smoke and other irritants recruit neutrophils and macrophages into the airways, which release proteases, especially neutrophil elastase, that degrade elastin in alveolar walls. Alpha-1 antitrypsin normally inhibits neutrophil elastase; when AAT is deficient or inhibited (as oxidants in smoke do), elastase activity goes unchecked.
This leads to progressive destruction of alveolar septa and capillary beds, with loss of elastic recoil and enlargement of airspaces. Two classic anatomic patterns are tested:
- Centriacinar (centrilobular) emphysema: affects the proximal respiratory bronchioles, predominantly in the upper lobes; classically associated with smoking.
- Panacinar (panlobular) emphysema: uniformly destroys the entire acinus, predominantly in the lower lobes; classically associated with AAT deficiency.
Loss of elastic recoil causes airway collapse during expiration, air trapping, and hyperinflation. Destruction of the capillary bed causes a ventilation-perfusion mismatch and impaired gas exchange, reducing diffusing capacity (DLCO). Patients compensate by hyperventilating, which helps maintain near-normal blood gases until late disease ('pink puffer' phenotype), in contrast to the chronic bronchitis phenotype where hypoxemia and hypercapnia develop earlier ('blue bloater').
Clinical features
- Progressive exertional dyspnea, often the dominant and earliest symptom.
- Minimal or scant sputum production (unlike chronic bronchitis).
- Pursed-lip breathing and use of accessory muscles.
- Barrel-shaped chest from hyperinflation.
- Weight loss and cachexia in advanced disease ('pink puffer').
- Decreased breath sounds, hyperresonance to percussion, and prolonged expiratory phase on exam.
- Clubbing is NOT typical of emphysema and should prompt a search for another diagnosis (e.g., lung cancer, bronchiectasis).
- In advanced disease: signs of right heart strain (cor pulmonale) can develop, though later than in chronic bronchitis.
Diagnosis
Diagnosis combines clinical history, spirometry, and imaging.
Spirometry (required for diagnosis of COPD)
- Obstructive pattern: reduced FEV1/FVC ratio (<0.70 post-bronchodilator confirms airflow limitation).
- Reduced FEV1 severity grades disease (GOLD 1-4).
- Increased total lung capacity and residual volume reflect air trapping; reduced DLCO reflects alveolar-capillary destruction.
Imaging
- Chest X-ray: hyperinflation, flattened diaphragms, increased retrosternal air space, decreased vascular markings.
- High-resolution CT chest: most sensitive for detecting and characterizing emphysema (bullae, upper vs lower lobe distribution).
Laboratory
- Arterial blood gas in advanced disease: may show hypoxemia; hypercapnia tends to occur later than in chronic bronchitis.
- Serum alpha-1 antitrypsin level should be checked in patients with early-onset emphysema, minimal smoking history, lower-lobe predominant disease, or a family history.
| Test | Typical finding in emphysema |
|---|---|
| FEV1/FVC | Decreased (<0.70) |
| TLC, RV | Increased |
| DLCO | Decreased |
| CXR | Hyperinflation, flat diaphragm |
Differential diagnosis
- Chronic bronchitis (the other COPD phenotype): productive cough for 3+ months in 2 consecutive years, earlier hypoxemia/hypercapnia, less hyperinflation.
- Asthma: typically reversible airflow obstruction, often younger onset, episodic symptoms, better bronchodilator response.
- Bronchiectasis: copious purulent sputum, recurrent infections, clubbing more common, tram-track/signet-ring sign on CT.
- Congestive heart failure: dyspnea with orthopnea, elevated BNP, pulmonary edema on imaging rather than hyperinflation.
- Lymphangioleiomyomatosis: cystic lung disease in young women, can mimic emphysema on imaging.
- Alpha-1 antitrypsin deficiency emphysema: distinguished by early onset, lower lobe predominance, and low serum AAT level.
Management
Management follows COPD guideline consensus (GOLD strategy, supported by ATS/ERS); emphysema-predominant and chronic bronchitis-predominant COPD are generally managed under the same framework, with select differences for severe bullous disease.
Foundational measures
- Smoking cessation is the single most important intervention and the only one proven to slow decline in lung function.
- Pulmonary rehabilitation for symptomatic patients.
- Vaccinations: influenza, pneumococcal, COVID-19, and pertussis-containing vaccine as indicated, to reduce exacerbations.
- Long-term oxygen therapy improves survival in patients with resting hypoxemia (per guideline thresholds).
Pharmacologic therapy
- Bronchodilators are first-line: long-acting muscarinic antagonists (LAMA, e.g., tiotropium) and/or long-acting beta-agonists (LABA, e.g., formoterol, salmeterol), used alone or in combination.
- Inhaled corticosteroids are added in patients with frequent exacerbations and higher eosinophil counts, generally as part of triple therapy (LAMA/LABA/ICS), not as monotherapy.
- Roflumilast (PDE4 inhibitor) may be considered in select patients with chronic bronchitis phenotype and frequent exacerbations.
- Short-acting bronchodilators (albuterol, ipratropium) for symptomatic relief and acute exacerbations.
- Alpha-1 antitrypsin augmentation therapy is specific to confirmed AAT deficiency with established disease.
Advanced and surgical options
- Lung volume reduction surgery or bronchoscopic valve therapy may benefit select patients with upper-lobe-predominant emphysema and low exercise capacity.
- Lung transplantation is considered in end-stage disease.
Acute exacerbations are treated with short-acting bronchodilators, systemic corticosteroids, antibiotics when indicated (increased purulence/sputum), and oxygen as needed, mirroring general COPD exacerbation protocols.
Complications and prognosis
- Respiratory failure (hypoxemic, and later hypercapnic in advanced disease).
- Cor pulmonale and right heart failure from chronic pulmonary hypertension.
- Spontaneous pneumothorax from rupture of subpleural bullae.
- Recurrent respiratory infections and acute exacerbations, which drive hospitalization and mortality.
- Secondary polycythemia from chronic hypoxemia.
- Lung cancer: smoking is a shared risk factor, and COPD itself is an independent risk factor.
Progression is generally irreversible and tends to be gradual, but the rate of FEV1 decline is markedly slowed by smoking cessation. Prognosis correlates with FEV1 severity, exacerbation frequency, body mass index, and exercise capacity (captured in composite indices such as BODE).
PINK PUFFER: Panacinar in AAT deficiency, Increased TLC/RV, No cyanosis early, Knife-thin build, Pursed lips, Upper-lobe centriacinar if smoker, Flattened diaphragm, Fights for air with accessory muscles, Elastase unopposed, Reduced DLCO.
Practice questions
1. A 62-year-old man with a 40-pack-year smoking history presents with progressive exertional dyspnea and minimal cough. Exam shows a barrel-shaped chest, decreased breath sounds, and pursed-lip breathing. Spirometry shows FEV1/FVC of 0.55 that does not normalize with bronchodilator. Which additional finding would be most expected?
2. A 34-year-old nonsmoker presents with dyspnea. CT chest shows emphysematous changes predominantly in the lower lobes. Which underlying mechanism is most likely responsible?
3. A 68-year-old woman with severe COPD (emphysema-predominant) has a resting SpO2 of 86% on room air, confirmed by arterial blood gas showing a PaO2 of 52 mmHg. Which intervention has been shown to improve survival in this setting?
Frequently asked questions
What causes emphysema?
Emphysema is caused by destruction of alveolar walls from an imbalance between proteases (especially neutrophil elastase) and protective antiproteases (especially alpha-1 antitrypsin). Cigarette smoking is the leading trigger, since it both recruits elastase-releasing neutrophils and inactivates alpha-1 antitrypsin. A genetic deficiency of alpha-1 antitrypsin causes a similar process even without smoking, typically producing earlier-onset, lower-lobe disease.
What are the first symptoms of emphysema?
The earliest and most common symptom is gradually worsening shortness of breath with exertion. Many patients also develop a mild chronic cough with little or no sputum, and some unconsciously adopt pursed-lip breathing to ease exhalation. Symptoms often go unnoticed for years because patients reduce activity to compensate, so significant lung function may already be lost by the time dyspnea is reported.
How is emphysema diagnosed?
Emphysema is diagnosed using spirometry, which shows an obstructive pattern with a reduced FEV1/FVC ratio that does not fully normalize after bronchodilator. Chest imaging, especially high-resolution CT, confirms hyperinflation and alveolar destruction, while reduced DLCO reflects loss of gas-exchange surface. Alpha-1 antitrypsin levels are checked when early-onset or lower-lobe disease is present.
Is emphysema curable?
No, emphysema is not curable because the alveolar destruction is permanent and lung tissue does not regenerate. Treatment focuses on slowing further damage, mainly through smoking cessation, and relieving symptoms with bronchodilators, pulmonary rehabilitation, and oxygen therapy when needed. Selected patients with severe disease may benefit from lung volume reduction procedures or transplantation, but these do not reverse the underlying destruction.
Emphysema vs chronic bronchitis — what is the difference?
Emphysema is defined by destruction of alveolar walls and airspace enlargement, causing dyspnea with minimal sputum ('pink puffer'), while chronic bronchitis is defined clinically by a productive cough lasting at least 3 months for 2 consecutive years, with earlier hypoxemia and hypercapnia ('blue bloater'). Both are subtypes of COPD, often coexist in the same patient, and are managed with largely overlapping guideline-based therapy.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: J43
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.